WO2000001814A2 - Nicht-menschliches säugetier, bei dem ein für ein scuz-protein kodierendes gen zeit- bzw. gewebespezifisch ausgeschaltet werden kann - Google Patents
Nicht-menschliches säugetier, bei dem ein für ein scuz-protein kodierendes gen zeit- bzw. gewebespezifisch ausgeschaltet werden kann Download PDFInfo
- Publication number
- WO2000001814A2 WO2000001814A2 PCT/DE1999/002055 DE9902055W WO0001814A2 WO 2000001814 A2 WO2000001814 A2 WO 2000001814A2 DE 9902055 W DE9902055 W DE 9902055W WO 0001814 A2 WO0001814 A2 WO 0001814A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- human mammal
- dna
- protein
- scuz
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 91
- 241000124008 Mammalia Species 0.000 title claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 47
- 239000000126 substance Substances 0.000 claims abstract description 7
- 238000012360 testing method Methods 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 18
- 101000844719 Mus musculus Deleted in malignant brain tumors 1 protein Proteins 0.000 claims description 16
- 108010091086 Recombinases Proteins 0.000 claims description 13
- 239000013598 vector Substances 0.000 claims description 13
- 102000018120 Recombinases Human genes 0.000 claims description 10
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 10
- 108700028369 Alleles Proteins 0.000 claims description 8
- 230000006798 recombination Effects 0.000 claims description 7
- 238000005215 recombination Methods 0.000 claims description 7
- 230000009471 action Effects 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 101150090288 DMBT1 gene Proteins 0.000 claims description 4
- 101000844718 Rattus norvegicus Deleted in malignant brain tumors 1 protein Proteins 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 230000002357 endometrial effect Effects 0.000 claims description 3
- 201000005619 esophageal carcinoma Diseases 0.000 claims description 3
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000010749 gastric carcinoma Diseases 0.000 claims description 3
- 201000005296 lung carcinoma Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000000498 stomach carcinoma Diseases 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 108091005725 scavenger receptor cysteine-rich superfamily Proteins 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 41
- 108020004414 DNA Proteins 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 108010051219 Cre recombinase Proteins 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108090000244 Rat Proteins Proteins 0.000 description 1
- 101710200251 Recombinase cre Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Definitions
- the present invention relates to a non-human mammal in which a gene coding for a protein is modified, the protein containing an SRCR, a CUB and a ZP domain.
- the invention further relates to a method for producing such a mammal and its use for testing substances which influence the protein.
- SRCR domain means "scavenger receptor cysteine rieh” domain. Such a domain comprises about 110 amino acids and is found in many proteins that are linked to elementary processes of the cell, e.g. Cell differentiation, cell-cell contact or immune response have to do, or act as receptors. Furthermore, the terms “CUB” domain and ZP "domain each relate to a defined protein region, which is important for protein / protein interactions.
- a human protein is known from the applicant's German patent 19730 997, which contains an SRCR, a CUB and a ZP domain. Its gene is called the DMBT1 gene and mapped to chromosome 10q25.3-q26.1. It is a tumor suppressor gene found in brain tumors, e.g. has homozygous deletions in 10% of medulloblastomas and 25% of glioblastomas, as well as in breast tumors (13%). It is also associated with carcinogenesis of lung carcinoma, melanomas, pancreas, endometrial, esophageal, colon and gastric carcinomas, as well as others, since about 40-50% of all tumors have chromosome 10q losses.
- genes from the mouse CCP-ductin gene
- the rat Ebnerin gene
- SCUZ proteins proteins containing such domains
- the object of the present invention is therefore to provide a means by which this can be investigated.
- a means should also be provided which can be used to test substances which have an effect on SCUZ proteins.
- an SCUZ protein can be investigated by means of a non-human mammal in which a gene which codes for an SCUZ protein is changed in such a way that it is either switched off or or tissue-specific can be switched off. He generated such a mammal by homologous recombination, using a vector construct which comprises the promoter and exon 1 of the CRP-ductin gene flanked by loxP sequences (cf. FIG. 2).
- the knowledge of the applicant is used to provide a non-human mammal in which a gene which codes for an SCUZ protein is changed such that it is switched off or can be switched off in a time-specific or tissue-specific manner.
- non-human mammal includes any mammal in which a gene may be altered that encodes an SCUZ protein. Examples of such mammals are mouse, rat, rabbit, horse, cattle, sheep, goat, monkey, pig, dog and cat, with mouse being preferred.
- an SCUZ protein includes any protein that contains at least one SRCR, one CUB and one ZP domain.
- the protein can be in wild-type or modified form, for example as a fusion protein or as a fragment, the modified form also comprising a modified amino acid sequence.
- the protein can be homologous or heterologous to the non-human mammal. In the latter case it may be beneficial if this is for the mammal homologous protein is turned off.
- the protein heterologous to the mammal can come from another mammal or from humans or another organism, for example the fruit fly.
- the above protein is preferably a human protein, for example the protein encoded by the DMBT1 gene, a mouse protein, for example the protein encoded by the CRP-ductin gene, or a rat protein, for example the protein encoded by the Ebnerin gene.
- modified gene indicates that a gene which codes for an SCUZ protein has been modified such that it is switched off or can be switched off in a time-specific or tissue-specific manner.
- the former can e.g. be achieved in that the gene has an insertion or deletion, whereby the gene no longer codes for the functional protein.
- a selection cassette such as neoTK is available.
- an exon or part thereof, such as the promoter and exon 1 of the CRP-ductin gene are missing.
- a time-specific or tissue-specific switching off of the gene e.g. be achieved in that it is under the control of an inducible or tissue-specific promoter.
- the gene can also have sequences that are recognized by a recombinase, whereby one or more parts of the gene are cut out after its activation, which leads to a deletion.
- sequences are e.g. loxP sequences recognized by a recombinase Cre.
- the recombinase can be activated by various measures.
- the recombinase gene can be under the control of an inducible or tissue-specific promoter and can already be present in the mammal in which the above gene is to be switched off.
- the recombinase gene can also be delivered to the mammal or its progeny, this being e.g. by conventional transfection methods or by crossing with another mammal that contains the recombinase gene.
- a non-human mammal according to the invention has the all shown in FIG. 3A! on. Particularly preferred is a non-human mammal that does the All indicated in Fig. 4C, 1st or 4C, 2nd! having. It is very particularly preferred if the non-human mammal is homozygous for the above allele.
- Another object of the present invention are cells obtained from the above non-human mammal. These cells can be in any form, e.g. in a primary or long-term culture.
- a non-human mammal according to the invention can be generated by conventional methods.
- a method is favorable which comprises the following steps:
- non-human mammal an SCUZ protein
- modified gene reference is made to the above statements.
- embryonic stem cells refers to any embryonic stem cells of a non-human mammal that are suitable for modifying a gene that codes for an SCUZ protein.
- the embryonic stem cells are preferably from the mouse, in particular the cells E14 / 1.
- Embryonic stem cells which contain a modified gene which codes for an SCUZ protein, the modification being such that the gene has sequences which can be recognized by a recombinase, are also a subject of the present invention.
- vector construct encompasses any vector construct which, by recombination with the DNA from embryonic stem cells, leads to a change in a gene which codes for an SCUZ protein, the change being such that the gene is switched off or in time - or tissue-specific can be switched off.
- the vector construct can comprise a DNA comprising an exon or part thereof of the above gene together with a selection marker, these elements being flanked by sequences which are recognized by a recombinase.
- the vector preferably comprises the promoter and exon 1 of the CRP-ductin gene together with the neoTK selection cassette, these elements being flanked with loxP sequences.
- DSMZ German Collection of Microorganisms and Cell Cultures
- Another object of the present invention is a nucleic acid, in particular DNA, which comprises the promoter and exon 1 of the CRP-ductin gene.
- the DNA preferably comprises the sequence of FIG. 1 or a sequence which differs from this by one or more base pairs, the latter sequence hybridizing with the sequence of FIG. 1 and not being a cDNA.
- hybridization indicates hybridization under customary conditions, in particular at about 20 ° C. below the melting point of the DNA used as the hybridization sample.
- a nucleic acid according to the invention, in particular DNA can be present as such or in the form of a vector, in particular an expression vector. Vectors are known to the person skilled in the art. A vector containing a nucleic acid according to the invention, in particular DNA, is therefore also the subject of the present invention.
- the present invention provides a non-human mammal in which a gene is altered which encodes an SCUZ protein, the alteration being such that the gene is switched off or can be switched off in a time-specific or tissue-specific manner.
- a mammal or cells from it With such a mammal or cells from it, the function or mode of action of an SCUZ protein can be examined. It is also possible to investigate the connection between a switched-off or modified SCUZ protein and the most different diseases, especially carcinomas.
- carcinomas are e.g. Brain tumors, breast tumors, lung carcinomas, melanomas, pancreas, endometrial, esophageal, colon and gastric carcinomas.
- the present invention thus also provides the basis for developing active substances with which the above diseases can be countered. Furthermore, it provides genomic sequences of the CRP-ductin gene, which contributes to the further understanding of genes that code for a SCUZ protein. These sequences also give the possibility of developing means with which the detection of such genes is possible or can be interfered with in the expression of the genes. Furthermore, the present invention provides non-human mammals, e.g. Sheep, cows, etc., in which large amounts of SCUZ proteins, especially those of humans, can be produced.
- FIG. 1 shows a DNA according to the invention, comprising the promoter
- Exon 1 of the CRP-ductin gene. 2 shows a DNA according to the invention which is present as an insert in the plasmid CRP-ductin KOK-creloxP.
- the DNA comes from the DNA of FIG. 1, ie it comprises the entire sequence (bp1-9312) of the DNA of FIG. 1. In this fragment, starting from the base pair 4114, there is a loxP sequence and an additional HindIII and Spell Interface comprehensive insert of approximately 74 bp inserted. From base pair 5336, the DNA also has a sequence insert of approximately 3.0 kb, which comprises a neoTK selection cassette with flanking loxP sequences.
- Fig. 3 shows the homologous recombination event between the inventive DNA of Fig. 2 and the CRP-ductin gene or the genotype obtained therefrom.
- Figure 4 shows homologous recombination events (1) and (2) that occur after the genotype of Figure 3 has been subjected to Cre recombinase treatment.
- the invention is illustrated by the example.
- Example 1 Generation of a non-human mammal according to the invention
- a mouse is generated in which the CRP-ductin gene is changed.
- a vector which contains the DNA from FIG. 1.
- This fragment has exons 1 and 2 of the CRP-ductin gene and its promoter.
- the fragment is modified in that from the base pair 4114 it has an insert of approximately 74 bp comprising a loxP sequence and an additional Hind III and Spel interface.
- the fragment from base pair 5336 has a sequence insert of approximately 3.0 kb, which comprises a neoTK selection cassette with flanking loxP sequences (cf. FIG. 2).
- This vector is generated by electroporation into mouse embryonic stem cells E14 / 1 introduced. This wears a brown fur. Stably transfected cells are obtained by selection with 350 ⁇ g / ml G418. Genomic DNA is isolated from these cells, digested with HindIII, electrophoretically separated and blotted. For the hybridization, a labeled DNA fragment, probe A, from FIG. 3 is used, which is flanking the 5 ′ end of the region that is suitable for homologous recombination on the left side. E14 / 1 cells are identified which are heterozygous, ie which contain a wild-type and a recombined allele (cf. FIGS. 3 and 4).
- a transient transfection with 5-30 ⁇ g of a Cre expression plasmid, for example pMC-Cre, before 1 ⁇ M Gancyclovir is added to them. This is used to select cells that have lost the neoTk selection cassette. Recombination event 1 or 2 is present in these cells (see FIG. 4).
- the former has a deletion of the neoTk selection cassette and is referred to as a "floxed allele. In hybridization with probe B, this shows an additional 2.1 kb Spel band in addition to the approximately 15 kb wild-type Spel band.
- the recombination event 2 has one Deletion of exon I and the neoTK selection cassette and is referred to as the “zero” mutant, which shows a 4 kb wild-type Bglll band and an additional 2.9 kb Bglll band when hybridized with probe B. a 15 kb wild-type spel band and an additional 13.5 kb spel band (see FIG. 4).
- the cells obtained are injected into C57BL / 6 mouse blastocysts. This wears a black fur.
- the blastocysts (12-15) are transferred to a sham pregnant mouse, B6D2-F1, and chimeric, black-brown mice are obtained. Chimeric females are crossed with C57B1 / 6 males, which ensures that offspring are preserved.
- Those with brown fur are analyzed by Southemblotting and / or PCR, whereby mice are identified which are heterozygous for the "floxed" allele or the "zero" mutant. By crossing heterozygous mice, homozygous mice are obtained.
- mice that contain a Cre recombinase gene under the control of a tissue-specific promoter mice that contain a Cre recombinase gene under the control of a tissue-specific promoter.
- Mice are obtained which are homozygous for the "floxed” allele and heterozygous for the Cre recombinase gene. It has been shown that a non-human mammal according to the invention can be obtained in which a gene which codes for an SCUZ protein is switched off or can be switched off in a time-specific or tissue-specific manner.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Animal Husbandry (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU58478/99A AU5847899A (en) | 1998-07-02 | 1999-06-30 | Non-human mammal wherein a gene coding for an scuz-protein can be de-activated in a time-specific or tissue-specific manner |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19829660.6 | 1998-07-02 | ||
DE1998129660 DE19829660C1 (de) | 1998-07-02 | 1998-07-02 | Nicht-menschliches Säugetier |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000001814A2 true WO2000001814A2 (de) | 2000-01-13 |
WO2000001814A3 WO2000001814A3 (de) | 2000-04-20 |
Family
ID=7872809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1999/002055 WO2000001814A2 (de) | 1998-07-02 | 1999-06-30 | Nicht-menschliches säugetier, bei dem ein für ein scuz-protein kodierendes gen zeit- bzw. gewebespezifisch ausgeschaltet werden kann |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU5847899A (de) |
DE (1) | DE19829660C1 (de) |
WO (1) | WO2000001814A2 (de) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996039513A2 (en) * | 1995-06-06 | 1996-12-12 | The Johns Hopkins University School Of Medicine | Ebnerin cloning of a secreted von ebner's gland protein |
WO1998030687A2 (de) * | 1997-01-09 | 1998-07-16 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Srcr domäne-enthaltendes protein |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19730997C1 (de) * | 1997-01-09 | 1998-09-24 | Deutsches Krebsforsch | SRCR Domäne-enthaltendes Protein |
-
1998
- 1998-07-02 DE DE1998129660 patent/DE19829660C1/de not_active Expired - Fee Related
-
1999
- 1999-06-30 AU AU58478/99A patent/AU5847899A/en not_active Abandoned
- 1999-06-30 WO PCT/DE1999/002055 patent/WO2000001814A2/de active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996039513A2 (en) * | 1995-06-06 | 1996-12-12 | The Johns Hopkins University School Of Medicine | Ebnerin cloning of a secreted von ebner's gland protein |
WO1998030687A2 (de) * | 1997-01-09 | 1998-07-16 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Srcr domäne-enthaltendes protein |
Non-Patent Citations (3)
Title |
---|
CHENG H ET AL: "CRP-ductin: a gene expressed in intestinal crypts and in pancreatic and hepatic ducts" ANAT REC, Bd. 244, Nr. 3, M{rz 1996 (1996-03), Seiten 327-343, XP000876877 * |
MOLLENHAUER J ET AL: "DMBT1, A NEW MEMBER OF THE SRCR SUPERFAMILY, ON CHROMOSOME 10Q25.3-26.1 IS DELETED IN MALIGNANT BRAIN TUMOURS" NATURE GENETICS,US,NEW YORK, NY, Bd. 17, Nr. 1, 1. September 1997 (1997-09-01), Seiten 32-39, XP002069502 ISSN: 1061-4036 * |
RAJEWSKY K ET AL: "Conditional gene targeting" J CLIN INVEST, Bd. 98, Nr. 3, 1. August 1996 (1996-08-01), Seiten 600-603, XP002130808 * |
Also Published As
Publication number | Publication date |
---|---|
WO2000001814A3 (de) | 2000-04-20 |
DE19829660C1 (de) | 1999-12-23 |
AU5847899A (en) | 2000-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69120146T2 (de) | Erzeugung xenogener antikörper | |
DE69233477T2 (de) | Transgene nicht-menschliche tiere ohne prionprotein | |
EP0658197B1 (de) | Gezielte ersetztung eines gens ohne endogene und selektienbare restsequenzen | |
DE69034238T2 (de) | Verfahren zur Erreichung einer Expression, oder zur Verbesserung der Expression eines Gens | |
DE69333082T2 (de) | Erzielen von homozygotem durch zielgerichtete genetische ereignisse | |
DE69833649T2 (de) | Ef-1-alpha transkriptionsregulatorische dna aus hamster | |
DE69133372T2 (de) | Transgenes, nicht-menschliches säugetier das die amyloidbildende pathologie der alzheimerschen krankheit zeigt | |
DE69333984T2 (de) | Androgen-regulierung durch dns sequenzen des rattenprobasin-gens | |
DE69233173T2 (de) | Herstellung eines Interesse-Proteins in der Milch eines Transgen-Säugetieres | |
DE60313499T2 (de) | Mutante nichtmenschliche säuger mit sigmarezeptormangel und anwendungen dafür | |
DE69534022T2 (de) | Genomische DNS Fragmente der regulierenden Sequenz der Beta 2 Untereinheit des neuronalen Nikotin-Acetycholin Rezeptors; damit transformierte transgene Tiere. | |
DE19829660C1 (de) | Nicht-menschliches Säugetier | |
DE19815958C1 (de) | Nicht-menschliches Säugetier sowie Verfahren zu seiner Herstellung und seine Verwendung | |
DE19625049A1 (de) | Transgenes, nicht-menschliches Säugetier, das ein zusätzliches DNA-Reparaturgen enthält | |
DE69838565T2 (de) | Nukleinsäuren von CIITA Genen | |
DE60031410T2 (de) | Mutiertes gen der gras familie und pflanzen mit reduzierter entwicklung, die dieses gen enhalten | |
WO1999028453A2 (de) | Transgenes nicht-menschliches säugetier mit einer onkogenen mutante des raf-1-gens | |
EP0386766A1 (de) | Verfahren zur gezielten Veränderung eines Gens | |
WO1999036528A2 (de) | Transgener nicht-menschlicher säuger sowie verfahren zu seiner herstellung und seine verwendung | |
DE60225046T2 (de) | Produktion eukaryontischer proteine und nukleinsäuremoleküle in c. elegans | |
DE4406512C1 (de) | Integrationsvektoren zur Herstellung von Genen, die rekombinante Antikörper codieren | |
WO2002017947A2 (de) | Verwendung von t-proteinen zur differentiellen charakterisierung und therapie von verletzungen und tumoren des nervensystems | |
DE10232151A1 (de) | Neuronal exprimierte Tryptophanhydroxylase und ihre Verwendung | |
DE19726824C1 (de) | Verfahren zur Identifizierung kanzerogener Agenzien | |
EP0675203B1 (de) | Integrationsvektoren zur Herstellung von Genen, die rekombinante Antikörper codieren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |